Table 5.
Distribution of examined markers according to subtypes
| |
Luminal A |
Luminal B |
Luminal-HER2 |
HER2-enriched |
TNBC |
BCP |
|---|---|---|---|---|---|---|
| N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |
|
alphaB-crystallin |
|
|
|
|
|
|
| Negative |
213 (93.4) |
299 (80.6) |
109 (83.8) |
88 (88.0) |
61 (55.0) |
41 (48.2) |
| Weakly positive |
8 (3.5) |
40 (10.8) |
16 (12.3) |
11 (11.0) |
24 (21.6) |
19 (22.4) |
| Strongly positive |
7 (3.1) |
32 (8.6) |
5 (3.8) |
1 (1.0) |
26 (23.4) |
25 (29.4) |
|
BRCA1 |
|
|
|
|
|
|
| Negative |
206 (92.0) |
334 (91.0) |
125 (97.7) |
95 (95.0) |
103 (94.5) |
79 (92.9) |
| Positive |
18 (8.0) |
33 (9.0) |
3 (2.3) |
5 (5.0) |
6 (5.5) |
6 (7.1) |
|
BRCA1
|
|
|
|
|
|
|
| WT |
19 (90.5) |
27 (100.0) |
11 (100.0) |
10 (100.0) |
11 (64.7) |
9 (60.0) |
| Mutated |
2 (9.5) |
0 |
0 |
0 |
6 (35.3) |
6 (40.0) |
|
p53 |
|
|
|
|
|
|
| Negative |
148 (67.3) |
154 (42.1) |
56 (43.8) |
41 (42.3) |
46 (43.0) |
32 (38.6) |
| Positive | 72 (32.7) | 212 (57.9) | 72 (56.3) | 56 (57.7) | 61 (57.0) | 51 (61.4) |
N, number; TNBC, triple-negative breast cancer; BCP, basal core phenotype; WT, wild-type.